outcomes of RECAP have been described previously (9) . Individuals who previously received pirfenidone or placebo treatment for 72-120 weeks in CAPACITY and received 2,403 mg/d pirfenidone during RECAP were included in the analyses. Individuals from ASCEND were not included due to lack of FVC follow-up data.
Association of baseline FVC (at entry into RECAP) with rate of FVC decline during RECAP (first aim) was assessed over 180 weeks using change from baseline in % predicted FVC, categorized by baseline % predicted FVC (,50%, >50% to ,60%, >60% to ,70%, >70% to ,80%, >80% to ,90%, and >90%).
Association of timing of pirfenidone initiation with annual FVC decline (ml/yr) during CAPACITY and RECAP (second aim) was assessed over 220 weeks by categorizing individuals who completed CAPACITY and enrolled in RECAP by CAPACITY treatment group (2,403 mg/d pirfenidone or placebo; the 1,197 mg/d pirfenidone group was not included). Annual FVC decline was calculated for Weeks 0-120 (CAPACITY), Weeks 72-120 (the transition period), and Week 120 onward (RECAP), as described in Figure 1 . This analysis was also stratified based on CAPACITY study of origin (004 or 006).
Results
FVC decline by baseline lung function. Overall, 584 individuals who entered RECAP with baseline FVC values were included in this analysis (median age, 69.0 years; male, 71.9%; white, 97.8%; median body mass index [BMI], 28.9 kg/m 2 ). At baseline, 28.6%, 52.2%, and 19.2% of individuals had a gender, age, and physiology (GAP) index of I, II, and III, respectively. Mean % predicted FVC and hemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DL CO ) at baseline in individuals with available data were 70.9% and 41.1%, respectively (baseline FVC: ,50%, n = 54; >50% to ,60%, n = 113; >60% to ,70%, n = 136; >70% to ,80%, n = 123; >80% to ,90%, n = 84; >90%, n = 74).
For all baseline FVC subgroups, mean declines in % predicted FVC over 180 weeks (2.5-4.3%) and annual rates of FVC decline (101.1-181.0 ml) during RECAP were similar (Figure 2 Supported by F. Hoffmann-La Roche, Ltd. (which was involved in study design, collection, analysis, and interpretation of the data).
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During CAPACITY, annual rate of FVC decline was 142.0 ml and 182.3 ml (-40.3 ml difference) in pirfenidone and placebo groups, respectively ( Figure 3 ). During RECAP, annual rate of FVC decline for previous pirfenidone and placebo groups, respectively, was 155.2 and 151.9 ml (3.3 ml difference) in the transition period and 145.3 and 140.9 ml (4.4 ml difference) after Week 120.
FVC decline in the placebo group in CAPACITY Study 006 was attenuated (3); therefore, this analysis was stratified based on CAPACITY study of origin. The difference between annual rate of FVC decline in the pirfenidone and placebo groups was larger during Study 004 (155.8 vs. 212.1 ml) than Study 006 (128.6 vs. 151.8 ml). Corresponding rates after CAPACITY were 123.2 versus 123.6 ml (previous Study 004) and 187.1 versus 184.7 ml (previous Study 006) during the transition period, and 138.5 versus 137.7 ml (previous Study 004) and 152.3 versus 144.4 ml (previous Study 006) after Week 120.
Discussion
These post hoc analyses of CAPACITY and RECAP found that long-term pirfenidone treatment had similar efficacy regardless of baseline FVC, and there was no effect of prior treatment on FVC change during RECAP. Importantly, loss of lung function that occurred before pirfenidone initiation was not recovered after initiation in RECAP, confirming that delaying antifibrotic treatment results in increased irreversible FVC loss. The efficacy of pirfenidone in reducing FVC decline was maintained for over 4 years, with little change in annual rate of FVC decline after more than 1 year of treatment in individuals who received pirfenidone during CAPACITY. These results are in line with previous analyses indicating that pirfenidone treatment is beneficial in individuals with IPF, regardless of stage of lung function or time since diagnosis at initiation (5, 10, 11). These findings are limited by the fact that they represent post hoc exploratory analyses, and that RECAP was an open-label extension study with no placebo group. Long-term follow-up might have introduced selection bias toward individuals with more preserved lung function over time, because they were less likely to discontinue treatment during CAPACITY or RECAP. In addition, individuals enrolled in CAPACITY had fewer comorbidities than are observed in unselected populations (3); thus, the benefits of initiating pirfenidone in individuals with more comorbidities could not be determined.
Overall, these results add weight to evidence supporting pirfenidone initiation at diagnosis in individuals with IPF to prevent irreversible loss of lung function. 
Using Syndromic Surveillance to Evaluate the Respiratory Effects of Fine Particulate Matter
To the Editor:
Particulate air pollution is a prevalent exposure in urban areas and has been linked to mortality and adverse respiratory conditions, including asthma, chronic obstructive pulmonary disease, lower respiratory infection, and lung cancer (1) (2) (3) . Studies of daily changes in fine particulate matter (aerodynamic diameter , 2.5 mm [PM 2.5 ]) and acute respiratory effects often use data from the healthcare system, typically acute care events, such as emergency department visits, hospital admissions, and to a lesser extent provider visits (4) (5) (6) . However, this approach may overlook some events, because patients presenting with subacute complaints may not initially seek care in these ways due to access (e.g., travel time), insurance coverage (e.g., copayments), or other factors such as presence of comorbidities (e.g., ability to travel). In addition, some subacute symptoms may not warrant emergency care but instead can be addressed through a primary care physician visit or contact with a nurse via phone or email. We adopted a syndromic surveillance framework to examine the relationship between ambient PM 2.5 concentrations and respiratory symptoms in a large health maintenance organizationbased healthcare system in the Mid-Atlantic region of the United States. Syndromic surveillance identifies changes in disease activity using either clinical features detected before diagnosis is confirmed or activities prompted by the onset of symptoms (7). We hypothesized that calls and e-mails related to respiratory symptoms would represent an association with PM 2.5 similar to the associations observed with emergency department and urgent care visits.
Methods
We constructed an innovative database of information collected during routine provision of medical care by Kaiser Permanente Mid-Atlantic States (KPMAS), which serves approximately 700,000 residents of the northern Virginia, District of Columbia, Maryland, and Baltimore areas. This study was approved by institutional review boards at KPMAS and Georgia State University.
Healthcare utilization data were collected from the comprehensive electronic health databases of KPMAS. We identified four types of utilization events for 2013 and 2014: 1) any phone contact or e-mail message (member or provider initiated); 2)
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